CRP reductions with Leronlimab in the setting of s
Post# of 148699
(Total Views: 556)
Posted On: 09/25/2024 1:01:35 PM
Re: HouseofCards #146622
CRP reductions with Leronlimab in the setting of severe COVID19 in addition to NASH have also been seen so I think it is a valid and logical marker for a primary endpoint. It is a very well recognized and common lab for clinicians so would be a useful marker during treatment post-approval.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...gure%202I).
Also (see figure 1):
https://pubmed.ncbi.nlm.nih.gov/33521616/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...gure%202I).
Also (see figure 1):
https://pubmed.ncbi.nlm.nih.gov/33521616/
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼